COMMENTARY
    Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
    By Shinya Sato September 28, 2026
    The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next major entrant in the fast-evolving market for obesity and metabolic dysfunction-associated steatohepatitis (MASH).Survodutide belongs to…

    LATEST

    Lenvima-Welireg Combo Gets US Nod for Advanced RCC
    September 28, 2026
    The US FDA on September 24 approved a combination therapy of Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) and US Merck’s hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor Welireg (belzutifan) for certain patients with renal cell carcinoma (RCC).The…
    Daiichi Sankyo Pulls US Filing for B7-H3 ADC in SCLC
    September 28, 2026
    Daiichi Sankyo has voluntarily withdrawn its US application for the B7-H3 directed antibody drug conjugate (ADC) ifinatamab deruxtecan in extensive-stage small cell lung cancer (ES-SCLC), the company said on September 25.The drug maker said the…
    Narcolepsy Diagnosis Still Takes Nearly 9 Years in Japan: Expert
    September 28, 2026
    Narcolepsy patients in Japan face an average delay of nearly nine years before receiving a definitive diagnosis, with limited access to appropriate care in some regions adding to the challenge, a Japanese sleep expert said…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COMMENTARY

    Regional Formularies Gain Ground, Raising Stakes for Drug Makers, Wholesalers
    By Tatsuya Otsuka

    Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…

    COLUMN

    The One Mistake on Your Resume
    By Philip Carrigan

    We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA